Prognostic Significance of Sites of Visceral Metastatic Disease in Prostate Cancer: A Population-based Study of 12,180 Patients

Budnik, J.; Suri, J.S.; Bates, James E.; Bylund, Kevin; Milano, Michael T.

doi:10.1016/j.clgc.2019.03.020

Cited by 18 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Adenocarcinoma is the most common prostatic tumor, whereas other histological subtypes such as urothelial, small cell, squamous cell, and basal cell carcinomas are diagnosed quite rarely (245). The major routes for PC progression include extracapsular extension and spread to pelvic lymph nodes, as well as metastasis to lungs and bones (246). Furthermore, given the abundant innervation of prostate peripheral zone, primary tumors arising in this area tend to escape the organ through perineural invasion (247).…”

Section: Tams and Prostate Cancermentioning

confidence: 99%

Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers

et al. 2020

View full text Add to dashboard Cite

Tumor-associated macrophages (TAMs) are major innate immune cells that constitute up to 50% of the cell mass of human tumors. TAMs are highly heterogeneous cells that originate from resident tissue-specific macrophages and from newly recruited monocytes. TAMs' variability strongly depends on cancer type, stage, and intratumor heterogeneity. Majority of TAMs are programmed by tumor microenvironment to support primary tumor growth and metastatic spread. However, TAMs can also restrict tumor growth and metastasis. In this review, we summarized the knowledge about the role of TAMs in tumor growth, metastasis and in the response to cancer therapy in patients with five aggressive types of cancer: breast, colorectal, lung, ovarian, and prostate cancers that are frequently metastasize into distant organs resulting in high mortality of the patients. Two major TAM parameters are applied for the evaluation of TAM correlation with the cancer progression: total amount of TAMs and specific phenotype of TAMs identified by functional biomarkers. We summarized the data generated in the wide range of international patient cohorts on the correlation of TAMs with clinical and pathological parameters of tumor progression including lymphatic and hematogenous metastasis, recurrence, survival, therapy efficiency. We described currently available biomarkers for TAMs that can be measured in patients' samples (tumor tissue and blood). CD68 is the major biomarker for the quantification of total TAM amounts, while transmembrane receptors (stabilin-1, CD163, CD206, CD204, MARCO) and secreted chitinase-like proteins (YKL-39, YKL-40) are used as biomarkers for the functional TAM polarization. We also considered that specific role of TAMs in tumor progression can depend on the localization in the intratumoral compartments. We have made the conclusion for the role of TAMs in primary tumor growth, metastasis, and therapy sensitivity for breast, colorectal, lung, ovarian, and prostate cancers. In contrast to other cancer types, majority of clinical studies indicate that TAMs in colorectal cancer have protective role for the patient and interfere with primary tumor growth

show abstract

Section: Tams and Prostate Cancermentioning

confidence: 99%

Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Lastly, we analyze current, relevant literature on this topic ( Table 3 ); we suggest future staging systems consider number of metastases, performance status, PSA kinetics, hemoglobin, pain, alkaline phosphatase, albumin, and lactate dehydrogenase. [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] Supplemental Table 2 shows that all studies were institutional or used large retrospective databases. We identify other factors that may be considered in prognostication.…”

Section: Discussionmentioning

confidence: 99%

Identification and Validation of the Prognostic Impact of Metastatic Prostate Cancer Phenotypes

Labe

Wang

Lehrer

et al. 2022

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

“…First, visceral metastases are recognized as an ominous prognostic sign. Visceral disease, particularly liver metastases, are known to be a poor prognostic factor [ 12 , 15 - 16 ]. A recent meta-analysis found the overall survival time for patients with bone metastases to be 21.3 months (95% CI, 20.8 to 21.9 months) as compared to 19.4 months for patients with lung metastases (95% CI, 17.8 to 20.7 months).…”

Section: Discussionmentioning

confidence: 99%

Evolving Natural History of Metastatic Prostate Cancer

Nafissi¹,

Kosiorek²,

Butterfield³

et al. 2020

Cureus

View full text Add to dashboard Cite

Prognostic Significance of Sites of Visceral Metastatic Disease in Prostate Cancer: A Population-based Study of 12,180 Patients

Cited by 18 publications

References 29 publications

Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers

Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers

Identification and Validation of the Prognostic Impact of Metastatic Prostate Cancer Phenotypes

Evolving Natural History of Metastatic Prostate Cancer

Contact Info

Product

Resources

About